Cipla Ltd. made a strong comeback in the second quarter of fiscal year 2020, buoyed by growth across key businesses, though launch timelines for its key respiratory inhalation generic, albuterol, in the US have been delayed.
The Indian company, which had a muted first quarter, reported overall revenue growth of 10% to INR43.96bn ($619m) in Q2,...







